Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Pinealon vs epitalon

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors epitalon

Pinealon (Glu-Asp-Arg) and epitalon (Ala-Glu-Asp-Gly) are short synthetic peptides from the same St. Petersburg institute. Pinealon is pitched for the brain and rests on rat and cell studies showing less oxidative damage in neurons. Epitalon is pitched for aging and has more data: telomerase activation in human cells, a lifelong mouse study with fewer tumors, and two Russian human studies reporting higher melatonin output, whose abstracts do not state design or sample size. The randomized trial often cited for epitalon tested the pineal extract Epithalamin, not the synthetic peptide, so neither has a randomized human trial of its own or an FDA approval. Epitalon is not on the 503A bulks list but is one of six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription; pinealon is not covered and has no federal basis to be compounded.

Verified: Verified Oct 28, 2026
EpitalonSponsoredFrom Bodybuilding Peptides

Which is better, Pinealon or epitalon?

Epitalon has the larger and more varied evidence base (human cell, lifelong mouse, and observational human reports). It was also reviewed by FDA's compounding advisory committee: FDA's drug center recommended against listing, the advisory committee voted in favor (HHS policy, Appendix B), and it is now covered by HHS's draft enforcement discretion policy. Pinealon has only rat and cell work from its developers and has never been nominated for compounding. The edge is relative: epitalon is graded human observational on two melatonin studies whose abstracts do not state design or sample size, pinealon is graded animal only, neither is proven to help people, and HHS's draft policy, which is not binding, does not change epitalon's evidence grade. [1] [5] [6] [7] [9] [10] [14] [15] [17]

How do Pinealon and epitalon compare?

Pinealon and Epitalon compared by dimension
DimensionPinealonEpitalonFavored
Structure [3] [5]Tripeptide Glu-Asp-Arg (EDR), a Khavinson short peptide bioregulator.Tetrapeptide Ala-Glu-Asp-Gly (AEDG), a synthetic version of the bovine pineal extract Epithalamin.
Proposed mechanism [2] [3] [5] [8]Limits reactive oxygen species and necrotic death in neurons and other cells under oxidative stress; developers propose it also acts on gene expression linked to Alzheimer's disease.Induces telomerase and lengthens telomeres in human cell cultures, through telomerase upregulation or the alternative lengthening pathway depending on the cell line.
Animal evidence [1] [6]Rats with prenatal hyperhomocysteinemia: offspring of treated mothers had better spatial learning and fewer necrotic cerebellar neurons.Lifelong study in female mice: some aging biomarkers slowed, the longest lived 10% lived longer, and spontaneous tumors fell, but mean life span did not change significantly.
Human evidence [4] [7] [14] [15]No controlled human trial. A Russian language review from the developers describes use of peptide bioregulators in people of various ages without trial detail.Two Russian studies reported higher melatonin output after the peptide; their abstracts do not state design or sample size. The randomized, placebo controlled trial often cited, which reported lower mortality in elderly people, tested the pineal extract Epithalamin, not synthetic epitalon.
Independent replication [1] [2] [3] [8]No independent replication identified; the studies cited here all come from the developing group.An independent UK laboratory reported telomere lengthening in human cell lines in 2025; no independent animal or human outcome study.
FDA and compounding status [9] [10] [11] [12] [17] [18]Never nominated for the 503A or 503B bulks lists, not an approved drug, and not covered by HHS's October 2026 draft policy, so a 503A pharmacy has no federal basis to compound it.Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection in intermittent courses) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).
Dosing [4] [7]No human dose established; supplement labeling in Russia is not based on a dose finding study.No human dose established; no human pharmacokinetic or dose ranging study has been published.
Safety [1] [6]No human safety data of any kind.No systematic human safety data; telomerase activation raises a theoretical question about existing tumors, although the mouse study found fewer tumors.
WADA status [13]Prohibited at all times under section S0 (non-approved substances).Prohibited at all times under section S0 (non-approved substances).
Typical cost [10] [12] [16] [17]No lawful price. Not available through licensed US channels; research chemical products sold for human use are unapproved drugs.No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Pinealon and Epitalon: grade, status, and cost
AttributePinealonEpitalon
ClassSynthetic tripeptide (Glu-Asp-Arg) from the Khavinson family of short peptide bioregulatorsSynthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract Epithalamin
What it isThree amino acid peptide from Russia's Khavinson bioregulator family, sold there as a brain supplement; rat and cell data only, no controlled human trial.4 amino acid peptide from a pineal gland extract: telomere and lifespan data in cells and mice, human melatonin studies of unstated design, not FDA approved.
EvidenceEvidence: Animal-only evidenceEvidence: Human observational evidence
FDA statusRegulatory: UnscheduledRegulatory: HHS interim policy (draft)
CompoundingPinealon is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing. Imported and research use only products are not verified for identity or purity.Epitalon is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 for insomnia: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds epitalon when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection, in intermittent courses), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add epitalon to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesOral capsule (sold as a supplement in Russia), Subcutaneous or intranasal use described by sellers (no studies), Injection (rat studies)Subcutaneous injection (as sold), Intramuscular injection (Russian Epithalamin reports), Intranasal and oral products exist without absorption data
Typical costNot available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Last verified

Has Pinealon been tested directly against epitalon?

No published trial has compared Pinealon and epitalon directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do Pinealon and epitalon cost?

Typical cost of Pinealon and Epitalon
DimensionPinealonEpitalon
Typical costNot available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Price detailPrice index in progressEpitalon price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Pinealon page and the Epitalon page.

Frequently asked questions

Are pinealon and epitalon the same thing?

No. Both are short synthetic peptides from the same St. Petersburg research group, but pinealon is three amino acids (Glu-Asp-Arg) aimed at the brain, and epitalon is four (Ala-Glu-Asp-Gly) modeled on a pineal gland extract and aimed at aging. [3] [5]

Which has better evidence?

Epitalon, though neither is strong. Epitalon has human cell studies, a lifelong mouse study, and two human studies of melatonin output whose abstracts do not state design or sample size. Pinealon has rat and cell studies only. Neither has a randomized human trial of the synthetic peptide. [1] [2] [5] [6] [7] [14] [15]

Does epitalon lengthen telomeres in people?

That has not been shown. Telomerase activation and telomere lengthening were measured in cultured human cells, not in people, and no human trial has measured telomere length after epitalon. [5] [8]

Can either be prescribed legally in the US?

Epitalon possibly, under conditions; pinealon, no. Epitalon is not FDA approved or on the 503A bulks list, but it is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection in intermittent courses) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Pinealon has never been nominated, is not covered, and has no federal basis to be compounded. State law still applies. [9] [10] [11] [17] [18]

Are they allowed in sport?

No. Both are unapproved substances prohibited at all times under WADA section S0. [13]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Arutjunyan A et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 2012PubMed 22567179, 2012
  2. [2]Khavinson V et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res 2011PubMed 21978084, 2011
  3. [3]Khavinson V et al. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules 2020PubMed 33396470, 2020
  4. [4]Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptide bioregulators in people of various age. Adv Gerontol 2013 (Russian language review)PubMed 24738258, 2013
  5. [5]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003PubMed 12937682, 2003
  6. [6]Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003PubMed 14501183, 2003
  7. [7]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
  8. [8]Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025PubMed 40908429, 2025
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
  10. [10]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Pinealon vs epitalon: evidence, cost, and legality. https://peptideagent.ai/compare/pinealon-vs-epitalon
HTML link
<a href="https://peptideagent.ai/compare/pinealon-vs-epitalon">Pinealon vs epitalon: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.